Brian Weinshenker

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion
    William F Schmalstieg
    Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA
    Neurology 78:540-4. 2012
  2. doi request reprint Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Continuum (Minneap Minn) 19:944-67. 2013
  3. ncbi request reprint Genetic variation in the B7-1 gene in patients with multiple sclerosis
    B G Weinshenker
    Department of Neurology, Mayo Clinic and Mayo Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Neuroimmunol 105:184-8. 2000
  4. pmc NMO-IgG: a specific biomarker for neuromyelitis optica
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dis Markers 22:197-206. 2006
  5. ncbi request reprint Neuromyelitis optica is distinct from multiple sclerosis
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 64:899-901. 2007
  6. ncbi request reprint Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker
    B G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55901, USA
    Curr Top Microbiol Immunol 318:343-56. 2008
  7. ncbi request reprint Neuromyelitis optica: what it is and what it might be
    Brian G Weinshenker
    Mayo Clinic Mayo Foundation, Rochester, MN 55902, USA
    Lancet 361:889-90. 2003
  8. ncbi request reprint Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 59:566-9. 2006
  9. ncbi request reprint Genetic variation in the transforming growth factor beta1 gene in multiple sclerosis
    B G Weinshenker
    Department of Neurology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Neuroimmunol 120:138-45. 2001
  10. ncbi request reprint Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system
    B G Weinshenker
    Department of Neurology, Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
    J Clin Apher 16:39-42. 2001

Research Grants

  1. Interferon Gamma Polymorphisms and Gender Bias in MS
    Brian Weinshenker; Fiscal Year: 2004

Detail Information

Publications44

  1. doi request reprint Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion
    William F Schmalstieg
    Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA
    Neurology 78:540-4. 2012
    ..To present a case series of patients with progressive myelopathy in the setting of a solitary demyelinating lesion...
  2. doi request reprint Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Continuum (Minneap Minn) 19:944-67. 2013
    ..This review defines current clinical criteria for diagnosis, differential diagnosis, and clinical evaluation of acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica, and summarizes principles of treatment...
  3. ncbi request reprint Genetic variation in the B7-1 gene in patients with multiple sclerosis
    B G Weinshenker
    Department of Neurology, Mayo Clinic and Mayo Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Neuroimmunol 105:184-8. 2000
    ..Selected variants of sufficient frequency were tested for an association with course and severity of MS and one was tested for an association with susceptibility; none of the association tests were positive...
  4. pmc NMO-IgG: a specific biomarker for neuromyelitis optica
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dis Markers 22:197-206. 2006
    ....
  5. ncbi request reprint Neuromyelitis optica is distinct from multiple sclerosis
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 64:899-901. 2007
  6. ncbi request reprint Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker
    B G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55901, USA
    Curr Top Microbiol Immunol 318:343-56. 2008
    ....
  7. ncbi request reprint Neuromyelitis optica: what it is and what it might be
    Brian G Weinshenker
    Mayo Clinic Mayo Foundation, Rochester, MN 55902, USA
    Lancet 361:889-90. 2003
  8. ncbi request reprint Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 59:566-9. 2006
    ..We investigated whether neuromyelitis optica (NMO) IgG seropositivity at the initial presentation of longitudinally extensive transverse myelitis (LETM) predicts relapse of myelitis or development of optic neuritis...
  9. ncbi request reprint Genetic variation in the transforming growth factor beta1 gene in multiple sclerosis
    B G Weinshenker
    Department of Neurology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Neuroimmunol 120:138-45. 2001
    ..Genetic variation in TGFB1 does not appear to contribute in a major way to susceptibility to MS...
  10. ncbi request reprint Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system
    B G Weinshenker
    Department of Neurology, Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
    J Clin Apher 16:39-42. 2001
    ..Plasma exchange should be considered for patients with idiopathic inflammatory demyelinating disease syndromes when they have failed corticosteroid therapy...
  11. ncbi request reprint Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange
    Mark Keegan
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Lancet 366:579-82. 2005
    ..0001). Patients with multiple sclerosis with pattern II pathology are more likely to respond favourably to TPE than are patients with patterns I or III...
  12. ncbi request reprint A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
    Claudia F Lucchinetti
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Brain 125:1450-61. 2002
    ..Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation...
  13. ncbi request reprint Brain abnormalities in neuromyelitis optica
    Sean J Pittock
    Department of Neurology, Laboratory Medicine and Pathology, Radiology, and Immunology, Mayo Clinic College of Medicine, Rochester, Minn, USA
    Arch Neurol 63:390-6. 2006
    ..We have, however, frequently encountered patients with a well-established diagnosis of NMO in whom either asymptomatic or symptomatic brain lesions develop suggesting that the diagnostic criteria for NMO should be revised...
  14. ncbi request reprint Not every patient with multiple sclerosis should be treated at time of diagnosis
    Sean J Pittock
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:611-4. 2006
  15. ncbi request reprint Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression
    Sean J Pittock
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905 0001, USA
    Arch Neurol 63:964-8. 2006
    ..Although it is conventionally believed that the brain is spared, brain imaging abnormalities are not uncommon in patients with NMO...
  16. ncbi request reprint Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN55905, USA
    Int J Radiat Oncol Biol Phys 66:1178-86. 2006
    ..The aim of this study was a retrospective assessment of neurotoxicity in patients with multiple sclerosis (MS) receiving external beam radiotherapy (EBRT) to the brain...
  17. ncbi request reprint Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
    Shanu F Roemer
    Department of Neurology, Mayo Clinic, College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Brain 130:1194-205. 2007
    ..These findings strongly support a role for a complement activating AQP4-specific autoantibody as the initiator of the NMO lesion, and further distinguish NMO from MS...
  18. ncbi request reprint Occurrence of CNS demyelinating disease in patients with myasthenia gravis
    Brian G Weinshenker
    Neurology 68:1326; author reply 1327. 2007
  19. ncbi request reprint Neuromyelitis optica
    Marcelo Matiello
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Neurol 20:255-60. 2007
    ..We concentrate on a recently identified serum antibody biomarker, neuromyelitis optica immunoglobulin G (NMO-IgG), which distinguishes neuromyelitis optica from multiple sclerosis...
  20. doi request reprint Laquinimod, a new oral drug for multiple sclerosis
    B Mark Keegan
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 371:2059-60. 2008
  21. ncbi request reprint The spectrum of neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Lancet Neurol 6:805-15. 2007
    ..The knowledge gained from further assessment of the exact role of NMO-IgG in the pathogenesis of neuromyelitis optica will provide a foundation for rational therapeutic trials for this rapidly disabling disease...
  22. doi request reprint Neuromyelitis optica and non organ-specific autoimmunity
    Sean J Pittock
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arch Neurol 65:78-83. 2008
    ..Neuromyelitis optica (NMO) is often associated with other clinical or serological markers of non-organ-specific autoimmunity...
  23. doi request reprint Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 65:349-57. 2008
    ..Interferon (IFN) gamma (IFNG) allelic variants are associated with susceptibility to multiple sclerosis (MS) in men but not in women...
  24. doi request reprint An approach to the diagnosis of acute transverse myelitis
    Anu Jacob
    Division of Neurology, Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom
    Semin Neurol 28:105-20. 2008
    ..We discuss the diagnostic clues and pitfalls of the not uncommon clinical scenario of a presumed "myelopathy with normal MRI." Finally, we suggest an algorithm for the diagnosis and management of acute myelopathies...
  25. ncbi request reprint OSMS is NMO, but not MS: proven clinically and pathologically
    Brian G Weinshenker
    Lancet Neurol 5:110-1. 2006
  26. ncbi request reprint Myeloperoxidase -463 (G-->A) polymorphism associated with lower risk of lung cancer
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:17-22. 2002
    ..To study the association of the myeloperoxidase (MPO) -463 (G-->A) polymorphism with lung cancer risk...
  27. ncbi request reprint CTLA4 is associated with susceptibility to multiple sclerosis
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    J Neuroimmunol 134:133-41. 2003
    ..005) for the 3'(514)*AT(8) allele. We did not detect linkage with MS susceptibility in multiplex families. We did not find a strong association with age at onset, disease course or severity. CTLA-4 is associated with susceptibility to MS...
  28. ncbi request reprint Neuromyelitis optica: clinical predictors of a relapsing course and survival
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Neurology 60:848-53. 2003
    ..Early prediction of a relapsing course and subsequent disease severity would facilitate design and implementation of clinical trials of such therapies...
  29. ncbi request reprint A population-based study of IL4 polymorphisms in multiple sclerosis
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    J Neuroimmunol 137:134-9. 2003
    ..54). We could not confirm the previously reported association between carriage of I3(709)*allele-2 and older age of onset. However, we found a trend for association between the homozygous state for this allele and older age of onset...
  30. ncbi request reprint CD95 polymorphisms are associated with susceptibility to MS in women. A population-based study of CD95 and CD95L in MS
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    J Neuroimmunol 146:162-70. 2004
    ..We did not find an association between CD95L and susceptibility to MS nor CD95 or CD95L and age of onset, disease course and disease severity...
  31. ncbi request reprint Bright red nuclei
    Sean J Pittock
    Department of Neurology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Neurology 62:619. 2004
  32. ncbi request reprint The natural history of recurrent optic neuritis
    Istvan Pirko
    Department of Neurology, Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 61:1401-5. 2004
    ..Optic neuritis (ON) may occur in isolation or may herald multiple sclerosis (MS) or neuromyelitis optica (NMO). Occasionally, ON may recur many times without intervening evidence of dissemination in space...
  33. ncbi request reprint A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
    Vanda A Lennon
    Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Lancet 364:2106-12. 2004
    ..We assessed the capacity of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple sclerosis...
  34. ncbi request reprint CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Neuroimmunol 169:137-43. 2005
    ..Furthermore it does not segregate with patterns of immunopathology in MS. We did not find an association between CCR5*Delta32 mutation and disease severity and age of onset in MS...
  35. ncbi request reprint Re: GAMES issue
    Brian G Weinshenker
    J Neuroimmunol 153:3-4. 2004
  36. ncbi request reprint Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"
    Chris H Polman
    VU Medical Center Amsterdam, Free University, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Neurol 58:840-6. 2005
    ..The 2005 Revisions to the McDonald Diagnostic Criteria for MS should simplify and speed diagnosis, whereas maintaining adequate sensitivity and specificity...
  37. ncbi request reprint Identifying disease modifying genes in multiple sclerosis
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    J Neuroimmunol 123:144-59. 2002
    ..This review addresses strategies relevant to identification of disease modifying genes in MS, and summarizes and critically evaluates the current state of knowledge in this area...
  38. ncbi request reprint Reply
    Chris H Polman
    Ann Neurol 59:871. 2006
  39. doi request reprint Acute disseminated encephalomyelitis: current understanding and controversies
    Nathan P Young
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Semin Neurol 28:84-94. 2008
    ..We review pathological differences between ADEM and MS in terms of their utility in the diagnosis of ADEM. Finally, we present a practical approach for management of patients suspected of having ADEM when the diagnosis is uncertain...
  40. ncbi request reprint Natural history of multiple sclerosis
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurol Clin 23:17-38, v. 2005
  41. ncbi request reprint Cerebrospinal fluid oligoclonal bands in the diagnosis of multiple sclerosis. Isoelectric focusing with IgG immunoblotting compared with high-resolution agarose gel electrophoresis and cerebrospinal fluid IgG index
    Alexandre S Fortini
    Departments of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Am J Clin Pathol 120:672-5. 2003
    ..The IEF method improves the sensitivity and the negative predictive value of the oligoclonal-banding assay, the IEF gels are easier to interpret, and the IEF assay requires a smaller cerebrospinal fluid volume...
  42. ncbi request reprint Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease
    Carlton W Thomas
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Inflamm Bowel Dis 10:28-31. 2004
    ..Inflammatory demyelinating disease of the central nervous system may be linked to anti-tumor necrosis factor alpha therapy...
  43. ncbi request reprint Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study
    Sean J Pittock
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Neurol 56:303-6. 2004
    ..This is important because these patients represent 17% of the entire prevalence cohort. These data should assist in the shared therapeutic decision-making process of whether to start immunomodulatory medications...
  44. ncbi request reprint Neuromyelitis optica: changing concepts
    Anu Jacob
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Neuroimmunol 187:126-38. 2007
    ..The development of animal models and further analysis of the association of NMO-IgG with disease severity and treatment response will elucidate the pathobiology of NMO...

Research Grants3

  1. Interferon Gamma Polymorphisms and Gender Bias in MS
    Brian Weinshenker; Fiscal Year: 2004
    ..If successful, this paradigm could be applied to a number of similar genetic association studies. ..